NASDAQ
6.15USD
+0.13 (+2.16%)
We have scored 4 news catalysts on Aura Biosciences, Inc. (AURA) over the past 12 months. The biggest single-day move next to one of them came Mar 18, 2026, when AURA closed −3.4%: “Auranova Resources and Kenorland Minerals Announce Upcoming 2026 Spring Drill Program at The South Uchi Project, Ontario”. Coverage across the window leans positive (average ticker sentiment +0.73). Most of the impact sits in price momentum and revenue cyclicality.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
636.1M
P/E
—
EPS
—
Beta
0.40
52W range
4.73-9.535
Day range
5.95–6.25
Open
6.01
Prev close
6.02
Volume
963.1K
Avg volume
686.1K
Dividend
0.00
IPO
2021-10-29
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Aura Biosciences, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for AURA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
